Biotech Industry Home to Some of the Strongest Performers in 2012
June 28 2012 - 8:20AM
Marketwired
Despite the recent economic slowdown, the Biotech Industry has been
home to some of the strongest performers in the market in 2012. The
SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca
Biotech Index ETF (FBT) year-to-date are up 30 percent and 32
percent, respectively. As the world continues to face evolving
health challenges the discoveries of new therapeutics and vaccines
are critical. Five Star Equities examines the outlook for companies
in the Biotech Industry and provides equity research on Lexicon
Pharmaceuticals, Inc. (NASDAQ: LXRX) and ZIOPHARM Oncology Inc.
(NASDAQ: ZIOP).
Access to the full company reports can be found at:
www.FiveStarEquities.com/LXRX
www.FiveStarEquities.com/ZIOP
Expiring patents have been a major dilemma for pharmaceutical
companies. New products that are being introduced are not expected
to generate the same level of revenues of the products that have
lost patent protection. The Obama administration is currently
analyzing a proposal in which the exclusivity period for biologics
would be cut down by 5 years. Mergers & Acquisitions activity
is expected to pick up in 2012 as companies scramble to look to
make up for loss revenues. M&A allow companies to acquire
products that are already proven in the market place without the
hassle and costs associated with research and development.
"Many of the pharmaceutical companies started producing
everything in-house out of their own R&D organizations and over
time they've failed to produce enough that way. So the industry is
now coalescing around a 50-50 model of half on your own and half
bought in. There are some things we'll do for ourselves but we need
to be constantly on the lookout for new technologies," said Angus
Russell, Chief Executive of Shire PLC.
Five Star Equities releases regular market updates on companies
in the Biotech Industry so investors can stay ahead of the crowd
and make the best investment decisions to maximize their returns.
Take a few minutes to register with us free at
www.FiveStarEquities.com and get exclusive access to our numerous
stock reports and industry newsletters.
Lexicon currently has five drug programs in mid-stage
development for diabetes, carcinoid syndrome, irritable bowel
syndrome, rheumatoid arthritis and glaucoma, all of which were
discovered by Lexicon's research team. The company recently
released positive results from their LX4211 Phase 2b trial for the
treatment of type 2 diabetes.
ZIOPHARM Oncology is a biopharmaceutical company focused on the
development and commercialization of new cancer therapies. The
company recently reported that the first patient has been dosed in
their Phase 3 study of palifosfamide for the treatment of small
cell lung cancer. Shares of the company have soared over 30 percent
year-to-date.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024